Predictive Oncology Issues Letter to Shareholders
Signature of Raymond F. Vennare, Chief Executive Officer Signature of Raymond F. Vennare, Chief Executive OfficerEAGAN, Minn., March 09, 2023...
COVID-19
Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System
The Ergo-Series maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures Ergo-Series...
Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights
CINCINNATI, March 09, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today...
Ocean Biomedical (NASDAQ: OCEA) Shares Detailed Research Data on Anti-Tumor Pathway Discoveries and Their Potential for Treatment of Non-Small Cell Lung Cancer, Metastatic Melanoma, and Glioblastoma by Scientific Co-founder
Illustration 1: Effect of anti-CHI3L1 on Primary Lung Cancer Illustration 2: Effect of bi-specific antibody on Glioblastoma tumorsProvidence, RI, March...
Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer
BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that...
Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines
Sandoz investment expected to be at least USD 400m – MOU signed today in Ljubljana at ceremony led by Slovenian...
Chiara Family Foundation Winter Classic hockey game raises $300,000 in support of the MUHC Foundation
Chiara Family Foundation Winter Classic hockey game raises $300,000 in support of the MUHC Foundation The game between Montreal Canadiens...
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks...
Novan Moves Forward with Unified Corporate Branding
– Novan is a fully integrated pharmaceutical company with proven capabilities across drug development through to commercialization – – EPI...
AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease
OCALA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma...
Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023
MINNEAPOLIS, March 08, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...
Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Data from Phase 1a Portion of ADVANCED-1 Trial of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer Expected...
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Topline Data Expected in 2Q 2023SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,...
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
FDA recommends additional revised primary symptom-based endpoints Revive to provide amended statistical analysis plan to support unblinding of the data...
ARCPOINT INC. PROVIDES CORPORATE UPDATE ON COST CUTTING INITIATIVES AND PRELIMINARY FINANCIAL RESULTS
Greenville, South Carolina, March 08, 2023 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) a leading US-based...
SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal
Safety and Immunogenicity Examined in Phase 1 Trial of GPS plus Anti–PD-1 Nivolumab in Patients with WT1-Expressing Relapsed Ovarian Cancer...
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical...
Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference
MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines...
AIM ImmunoTech Issues Letter to Stockholders
Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity...
Surgalign Provides Update on Corporate Restructuring Initiatives and Confirms its Prior 2022 Revenue Guidance
Company on track to achieve target cash savings of $30 - $35 million in 2023 vs 2022; expects to report...